- Home
- PETS vs CTSO Comparison
PETS vs CTSO Comparison
Compare PETS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | CTSO |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 45.7M |
| IPO Year | 2003 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PETS | CTSO |
|---|---|---|
| Price | $2.60 | $0.79 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.20 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 135.6K | 67.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | $2.98 | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $1.57 | $0.60 |
| 52 Week High | $4.32 | $1.39 |
Technical Indicators
Market Signals| Indicator | PETS | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 70.35 |
| Support Level | $2.44 | $0.81 |
| Resistance Level | $2.93 | $0.85 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 9.68 | 92.63 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.